Cuts to CV Sales Force

Quote
Rightly so is correct. companies have no problem selling their drugs in other countries for much cheaper. Why should the US consumer be forced to pay multiple times more than other countries. Pharma preaches it’s all about research and development so US consumer needs to pay. BS… don’t sell your drug in other countries if it’s such a bad deal.
 






The pricing for all of healthcare is screwed up and drugs are certainly no exception. Everything‘s jacked up to three times the amount it should cost and then it’s a discounted by 50 to 60%. It’s really quite stupid. The only person that ends up paying full price is a person with no insurance.
 






anonymous said:
Rightly so is correct. companies have no problem selling their drugs in other countries for much cheaper. Why should the US consumer be forced to pay multiple times more than other countries. Pharma preaches it’s all about research and development so US consumer needs to pay. BS… don’t sell your drug in other countries if it’s such a bad deal.
Click to expand...
The answer is simple, and it is in-house.
Fire Vas and fill the position with Duane K.
Within 60 days he'll be giving everything away, and offering double-credit to make sure everyone gives away as much as possible.
Free meds for everybody, and fake sales numbers for senior management to present to the shareholders.
What could go wrong?
 


















Novartis CV is basically a contract job in the past decade+…except there’s no known end date. Anyone in CV should expect layoffs at some point and only use it as a stepping stone or place holder.
 


















Not going to happen in Oct. Need to squeeze every $ can from Entresto before goes generic. Would make sense to do before Vegas meeting. That means above poster prob correct. Novartis will take all to Vegas. Tell us all valued we are, how its for the patient to get them on Entresto before goes generic. Layoff once generic entry to market. Dont believe they will layoff cv2 as a whole. It will be like before.
 












anonymous said:
Not going to happen in Oct. Need to squeeze every $ can from Entresto before goes generic. Would make sense to do before Vegas meeting. That means above poster prob correct. Novartis will take all to Vegas. Tell us all valued we are, how its for the patient to get them on Entresto before goes generic. Layoff once generic entry to market. Dont believe they will layoff cv2 as a whole. It will be like before.
Click to expand...
I think it will be more like having only one representative per geography now. Entresto has been on cruise control for quite a while now and you really don’t need that extra push anymore. It is what it is. They literally destroyed the entire CV division with the half assed launch of Leqvio.
 






anonymous said:
I think it will be more like having only one representative per geography now. Entresto has been on cruise control for quite a while now and you really don’t need that extra push anymore. It is what it is. They literally destroyed the entire CV division with the half assed launch of Leqvio.
Click to expand...
Cuts before Vegas mark my word, but not as bad as people envision, but as the old saying goes one is one too many especially if you happen to be that one
 






anonymous said:
I think it will be more like having only one representative per geography now. Entresto has been on cruise control for quite a while now and you really don’t need that extra push anymore. It is what it is. They literally destroyed the entire CV division with the half assed launch of Leqvio.
Click to expand...
"They literally destroyed the entire CV division with the half-assed launch of Leqvio".

It wasn't half-assed, as that gives half an ass far too much credit.
Watching Dez, Duane, Jeff and Sandeep play grabass while the division was reduced to rubble was a truly remarkable spectacle.
That Dez and Duane are still here tells you how much Victor cares.
 






This is a rhetorical question, but had it been priced at say 50% of what it is, do you think it would be double or more times the sales VOLUME that it is…IDK but you’ve got to wonder if “taking a hit” initially pays off in the longer run. Parity pricing worked for many years, but I’m not sure it’s what is advantageous in today’s environment. We should own this space based on efficacy and dosing, so something is off.
 






anonymous said:
This is a rhetorical question, but had it been priced at say 50% of what it is, do you think it would be double or more times the sales VOLUME that it is…IDK but you’ve got to wonder if “taking a hit” initially pays off in the longer run. Parity pricing worked for many years, but I’m not sure it’s what is advantageous in today’s environment. We should own this space based on efficacy and dosing, so something is off.
Click to expand...
This sales team is so fucking under-qualified to sell this drug. You fucking idiot. One of the reason it’s not going well is because it’s a buy and bill drug that is priced so low? Stupid fuck. The price being so low is what makes it unattractive. Jesus.
 






anonymous said:
This is a rhetorical question, but had it been priced at say 50% of what it is, do you think it would be double or more times the sales VOLUME that it is…IDK but you’ve got to wonder if “taking a hit” initially pays off in the longer run. Parity pricing worked for many years, but I’m not sure it’s what is advantageous in today’s environment. We should own this space based on efficacy and dosing, so something is off.
Click to expand...
Price? Maybe you've forgotten that we gave it away for free for 12 months. How did that work out?
 






anonymous said:
This sales team is so fucking under-qualified to sell this drug. You fucking idiot. One of the reason it’s not going well is because it’s a buy and bill drug that is priced so low? Stupid fuck. The price being so low is what makes it unattractive. Jesus.
Click to expand...
You are not wrong. If our offices put big bank in their pockets like the oncology offices do with buy and bill. Leqvio would be rolling. A couple of percent on 3k is nothing and most places lose money unless they have 340b pricing. Having to ask offices to buy more watermelons when they lose money on each batch isn't going to fly long term. Novartis will never make a dollar of profit on Leqvio.
 






anonymous said:
This sales team is so fucking under-qualified to sell this drug. You fucking idiot. One of the reason it’s not going well is because it’s a buy and bill drug that is priced so low? Stupid fuck. The price being so low is what makes it unattractive. Jesus.
Click to expand...
Novartis never bothered to train themselves or retrain the sales force on buy and bill. They also ignore account based selling in favor of provider based metrics and have reps focused on sample dropping instead of developing accounts. Pharma isn’t buy and bill and buy and bill isn’t pharma. Yet sales training still thinks we are asking providers to “prescribe” Leqvio.
So yes, the team is under qualified, but mostly because Novartis leadership doesn’t understand the buy and bill market to train their pharma reps into becoming B&B reps.
 






I think Novartis will piggyback on the Xolair layoff announcement and layoff reps in CV, leaving one rep per territory. Gives everyone who is left behind time to reassess their new geography in the dog days of November and December. Then get all pumped up at the Vegas meeting.
 






anonymous said:
I think Novartis will piggyback on the Xolair layoff announcement and layoff reps in CV, leaving one rep per territory. Gives everyone who is left behind time to reassess their new geography in the dog days of November and December. Then get all pumped up at the Vegas meeting.
Click to expand...
That can’t happen until they’ve submitted to Warn and they have not yet.
 






Top Bottom
Back
Quote